Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.

Multidrug-resistant gram-negative infections (MDRGNIs) are an emerging and deadly threat worldwide. Some of these infections are now resistant to nearly all antibiotics, and very few treatment options ...

Hospital uptake of newer antibiotics to treat multidrug-resistant gram-negative bacteria was low over a 5-year period, according to a retrospective cohort study. Fully 41.5% of episodes of ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...

New guidance from the Infectious Diseases Society of America provides practitioners with actionable information for the treatment of antimicrobial-resistant gram-negative pathogens, including extended ...

Urinary tract infections (UTIs) are common, but increasingly hard to treat because the bacteria that cause them are developing resistance to many antibiotics. Researchers headed by a team at the ...

Please provide your email address to receive an email when new articles are posted on . “What antibiotic should I use to treat this patient’s Klebsiella pneumoniae? It’s resistant to carbapenems, and ...

​As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.

Infections caused by gram-negative bacteria have features that are of particular concern. These organisms are highly efficient at up-regulating or acquiring genes that code for mechanisms of ...

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that it will be receiving an additional $400,000 from the ...